ATE203676T1 - Karzinombehandlung - Google Patents

Karzinombehandlung

Info

Publication number
ATE203676T1
ATE203676T1 AT95938518T AT95938518T ATE203676T1 AT E203676 T1 ATE203676 T1 AT E203676T1 AT 95938518 T AT95938518 T AT 95938518T AT 95938518 T AT95938518 T AT 95938518T AT E203676 T1 ATE203676 T1 AT E203676T1
Authority
AT
Austria
Prior art keywords
carcinoma treatment
treatment
carcinoma
carcinomas
inducer
Prior art date
Application number
AT95938518T
Other languages
English (en)
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Application granted granted Critical
Publication of ATE203676T1 publication Critical patent/ATE203676T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT95938518T 1994-12-13 1995-12-01 Karzinombehandlung ATE203676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (1)

Publication Number Publication Date
ATE203676T1 true ATE203676T1 (de) 2001-08-15

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938518T ATE203676T1 (de) 1994-12-13 1995-12-01 Karzinombehandlung

Country Status (12)

Country Link
EP (1) EP0806963B1 (de)
JP (1) JP4076230B2 (de)
AT (1) ATE203676T1 (de)
AU (1) AU691996B2 (de)
CA (1) CA2207779C (de)
DE (1) DE69522012T2 (de)
FI (1) FI118918B (de)
GB (1) GB9425060D0 (de)
MX (1) MX9704372A (de)
NO (1) NO318587B1 (de)
NZ (1) NZ296161A (de)
WO (1) WO1996018413A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PL1680141T3 (pl) * 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
ES2400660T3 (es) 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ592159A (en) * 2005-12-09 2012-12-21 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
NO972732L (no) 1997-06-13
FI972484A0 (fi) 1997-06-12
NZ296161A (en) 2001-10-26
MX9704372A (es) 1998-02-28
CA2207779A1 (en) 1996-06-20
DE69522012T2 (de) 2002-04-25
DE69522012D1 (de) 2001-09-06
AU691996B2 (en) 1998-05-28
FI118918B (fi) 2008-05-15
EP0806963A1 (de) 1997-11-19
GB9425060D0 (en) 1995-02-08
NO972732D0 (no) 1997-06-13
CA2207779C (en) 2009-10-06
AU3988495A (en) 1996-07-03
FI972484L (fi) 1997-06-12
JP4076230B2 (ja) 2008-04-16
NO318587B1 (no) 2005-04-11
EP0806963B1 (de) 2001-08-01
JPH10510526A (ja) 1998-10-13
WO1996018413A1 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
DE69522012D1 (de) Karzinombehandlung
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
DE69115182D1 (de) Polymerzusammensetzung und ihre Verwendung.
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
ES292314U (es) Un articulo sanitario
NO912625L (no) Betongstein belagt med kopolymerfilm, samt fremgangsmaate for fremstilling av betongsteinen.
DE3381909D1 (de) Phthalazin substituierte aminomethylbenzolabkoemmlinge, zusammensetzungen und verwendung.
TW355847B (en) A surface treatment steel plate used for battery case, batterycase and battery using the case
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
NO902532D0 (no) Fremgangsmaate for fremstilling av flytebro, samt flytebrofortrinnsvis fremstillet i henhold til fremgangsmaaten.
DE3674079D1 (de) Bindercopolymerzusammensetzung und damit behandelte papiere.
HRP930344B1 (en) New retinoides
FI88228C (fi) Dielektrisk resonatorkonstruktion
ES2013025A6 (es) Un metodo para preparar 24r-escimnol.
FR2661829B1 (fr) Nouvelles compositions hydratantes et protectrices pour le bronzage notamment sans soleil.
ES8504419A1 (es) Procedimiento para la sensibilizacion al calor de dispersiones acuosas de polimero.
DE59106847D1 (de) Überzugsmittel sowie dessen Verwendung.
Denniston “Illuminations” for wind ensemble
KR900014715U (ko) 냉, 온열기의 연료절약기
IT8403421V0 (it) Biadesivo in custodia telefonica, posizionato nella parte interna del la stessa e specificatamente sul dorso spessore
KR940018863U (ko) 온, 난방 장치를 구비한 식탁
TR200002469T2 (tr) İkameli 1,2,4-triazol [3,4-a]piridazin.
ES261290Y (es) Estuche triptico para anotaciones, direcciones y telefonos con calendario incorporado.
UA33864A (uk) Кардіотонічний засіб суфан у вигляді супозиторіїв